TIDAL-01 is under clinical development by Turnstone Biologics and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs for Melanoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TIDAL-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TIDAL-01 overview
Turnstone Biologics overview
Turnstone Biologics, a subsidiary of Turnstone Biologics Corp, is a clinical stage biotech company engaged in developing breakthrough cancer immunotherapies and drugs for the treatment of solid tumors. The company is headquartered in Ottawa, Ontario, Canada.
For a complete picture of TIDAL-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.